Table 3.
Demographic and clinical factors associated with attrition during pre-ART Care in children (aged 18 months – < 15 years) enrolled under IHC Program between Jan 2005 – June 2016 (n = 2592).
| Patient’s characteristics | Number | Attrition (N) | Attrition (per 100 persons-year follow-up) (95% Cl) | Unadjusted hazard ratio (95% Cl) | Adjusted hazard ratio (95% Cl) | P value |
|---|---|---|---|---|---|---|
| Total | 2592 | 332 | 18.9(17.0–21.1) | |||
| Gender | ||||||
| male | 1370 | 177 | 19.3 (16.6–22.3) | ref | ref | |
| female | 1222 | 155 | 18.6 (15.9–21.8) | 0.9 (0.8–1.2) | 0.9 (0.8–1.2) | 0.580 |
| Age | ||||||
| 18 months to < 5 years | 800 | 108 | 16.3 (13.5–19.7) | ref | ref | |
| 5 years to < 10 years | 1131 | 145 | 18.2 (15.5–21.4) | 0.9 (0.8–1.3) | 0.9 (0.6–1.2) | 0.363 |
| 10 years to < 15 years | 661 | 79 | 27.0 (21.7–33.7) | 1.1 (0.8–1.5) | 0.9 (0.6–1.1) | 0.345 |
| Growtha | ||||||
| Normal | 408 | 38 | 8.3 (6.0–11.4) | ref | ref | |
| Underweight (<-2 Z-score) | 1958 | 205 | 16.7 (14.5–19.1) | 1.5 (1.0–2.1) | 1.9 (1.3–2.8) | 0.002 |
| Overweight (> 2 Z-score) | 100 | 6 | 16.3 (7.3–36.3) | 1.0 (0.4–2.4) | 1.2 (0.5–2.9) | 0.650 |
| Unknown | 126 | 83 | 323.7 (261.1–401.4) | 14.0 (9.5–20.1) | 5.8 (3.5–9.6) | < 0.001 |
| Haemoglobin(baseline) | ||||||
| No anaemia | 515 | 28 | 5.6 (3.9–8.2) | ref | ref | |
| Mild | 429 | 23 | 6.5 (4.3–9.7) | 1.0 (0.6–1.8) | 1.0 (0.6–1.8) | 0.9 |
| Moderate | 1217 | 77 | 9.8 (7.9–12.3) | 1.4 (0.9–2.2) | 1.3 (0.9–2.0) | 0.2 |
| Severe | 213 | 21 | 33.7 (21.9–51.7) | 2.9 (1.7–5.3) | 2.7 (1.5–4.9) | 0.001 |
| Unknown | 257 | 183 | 335.1 (289.9–387.3) | 27.0 (18.0–40.5) | 9.2 (5.4–16.7) | < 0.001 |
| WHO stage (baseline) | ||||||
| Stage 1 | 680 | 85 | 12.3 (9.9–15.3) | ref | ref | |
| Stage 2 | 596 | 62 | 13.6 (10.6–17.4) | 0.9 (0.7–1.3) | 0.9 (0.7–1.4) | 0.8 |
| Stage 3 | 1153 | 137 | 24.2 (20.5–28.6) | 1.3 (1.0–1.7) | 1.1(0.8–1.5) | 0.5 |
| Stage 4 | 177 | 29 | 84.2 (58.5–121.2) | 2.4 (1.5–3.6) | 1.8 (1.1–2.8) | 0.01 |
| Unknown | 25 | 19 | 302.7 (193.1–474.6) | 9.8 (5.9–16.1) | 0.4 (0.2–0.7) | < 0.001 |
| Immunological staging (CD4 count/cd4 %) | ||||||
| No | 608 | 61 | 6.5 (5.1–8.4) | ref | ref | |
| Mild | 297 | 15 | 6.3 (3.8–10.5) | 0.7 (0.4–1.2) | 0.7 (0.4–1.3) | 0.205 |
| Advance | 407 | 16 | 8.9 (5.5–14.5) | 0.7 (0.4–1.2) | 0.8 (0.4–1.4) | 0.415 |
| Severe | 976 | 51 | 18.9 (14.4–24.9) | 1.1 (0.8–1.6) | 1.1 (0.8–1.7) | 0.483 |
| Unknown | 343 | 189 | 148.3 (128.6–171.0) | 11.2 (8.3–15.1) | 2.0 (1.2–3.3) | 0.006 |
| Hepatitis B infection(baseline) | ||||||
| Negative | 2405 | 247 | 14.8 (13.0–16.7) | ref | ref | |
| Positive | 65 | 6 | 14.9 (6.7–33.3) | 1.1 (0.5–2.5) | 1.2 (0.5–2.6) | 0.700 |
| Unknown | 161 | 79 | 198.5 (159.2–247.5) | 7.1 (5.5–9.2) | 1.9 (1.4–2.6) | |
| Previous TB history | ||||||
| Absent | 1827 | 276 | 19.4 (17.3–21.8) | ref | ref | |
| Present | 804 | 56 | 17.0 (13.1–22.1) | 0.6 (0.4–0.7) | 0.7 (0.5–0.9) | 0.020 |
aWeight-for-age Z-score or BMI; HIV-human immunodeficiency virus, IHC-integrated HIV care